Strong Memorial Hospital

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Stroke5 trials
• Aortic stenosis2 trials
• Acute myeloid leukaemia1 trial
• Atrial fibrillation1 trial
• Chronic myeloid leukaemia1 trial
• Coronary artery disease1 trial
• Heart failure1 trial
• Myelodysplastic syndromes1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Completed3 trials
• Recruiting3 trials
• Active, not recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Novartis Pharmaceuticals2 trials
• Yale University2 trials
• Medtronic Cardiovascular1 trial
• Skribe Medical1 trial
• Takeda1 trial
• and 2 more

Running trials

• Enrolling by invitation

  Novel On-body Evaluation of Cardiac Health for Oncology

  NCT07158450· Skribe Medical· Source

• Recruiting

  A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

  NCT05646381· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Ferogh Shakouri

• Active, not recruiting

  Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

  NCT05047172· Phase 3· University of Florida· Source

• Recruiting

  Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

  NCT05338697· Yale University· Source

  Contact: Ania Busza, MD, PhD

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Yale University· Source

  Contact: Curtis Benesch, MD

• Active, not recruiting

  Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

  NCT02701283· Medtronic Cardiovascular· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke2 recruiting
• Aortic stenosis1 recruiting
• Atrial fibrillation1 recruiting
• Heart failure1 recruiting

Closed trials

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Sleep for Stroke Management and Recovery Trial

  NCT03812653· University of Michigan· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Takeda· Source